gene therapies

Benchling has launched its first full set of capabilities for designing, modeling, and studying both natural and chemically modified RNA in a single solution. As the biopharmaceutical industry increases its focus on developing RNA therapeutics, the new RNA solution could help R&D organisations accelerate the delivery of drug candidates. Following the successful deployment of RNA […]

A Phase I/II clinical trial targeting a treatment for Huntington’s Disease (HD) using a gene therapy has been given the clearance to go ahead in France.  The National Agency for Safety of Medicines and Health Products (ANSM) gave the go-ahead to Bayer AG to conduct the clinical trial through its subsidiary BrainVectis to investigate its […]

Scientists have identified a new class of targeted cancer drugs that offer the potential to treat patients whose tumours have faulty copies of the BRCA cancer genes. The drugs, known as POLQ inhibitors, specifically kill cancer cells with mutations in the BRCA genes while leaving healthy cells unharmed. Crucially, they can kill cancer cells that […]

The ELRIG Cell & Gene Therapy meeting will be held virtually on May 18-19, 2021. This interactive two-day conference will host scientists from academia and industry to discuss current and future perspectives of cell and gene therapies. Cell and gene therapies are rapidly evolving, revealing many new therapeutic opportunities not previously amenable to drug discovery. […]

How do we know the medicines we take are safe and effective from batch to batch? Medicinal products like erythropoietin and gene therapies can be very challenging to quality control. Dr Mark Lies, Global Business Manager of Capillary Electrophoresis, SCIEX describes how capillary electrophoresis is being applied to address these challenges and ensure medicinal constituents […]